BillionToOne, Inc. (BLLN) is a Menlo Park, California-based precision molecular diagnostics company that went public on Nasdaq in November 2025. The company's Quantitative Counting Templates (QCT) platform underpins non-invasive prenatal screening and oncology liquid biopsy tests, including its UNITY Complete and Northstar products. After a volatile first year as a public company, the stock traded near $103.50 at the most recent close, well below its 52-week high of $150.44. The question investors are asking is whether the shares can climb back toward a $125 price target.
BillionToOne carries relatively light but clearly bullish sell-side coverage following its late-2025 IPO. I reviewed seven current, individually attributed targets. The most recent actions include Guggenheim raising its target to $128 from $125 in early October 2026, and Canaccord Genuity initiating coverage with a Buy and a $120 target in September 2026. After the company's August earnings report, J.P. Morgan lowered its target to $130 from $145, BTIG trimmed its target to $130 from $142, Stifel held at $145, Piper Sandler reiterated $120, and Wells Fargo maintained a Hold with a $90 target.
These seven targets — $145, $130, $130, $128, $120, $120, and $90 — average about $123, which I round to a $125 central target. The range is unusually wide, from $90 to $145, reflecting genuine disagreement about the durability of growth and the appropriate valuation for a company trading at a triple-digit price-to-earnings (P/E) ratio. Most analysts emphasize the firm's differentiated single-molecule sequencing technology and strong prenatal and oncology positioning, while the lone Hold reflects concerns about reimbursement risk and a stretched valuation.
At roughly $103.50, BLLN sits about 31% below its 52-week high of $150.44 and well above its 52-week low of $61.96. Reaching $125 would require a gain of approximately 21%, which I would characterize as a substantial move. The stock has already demonstrated it can trade well above $125, having reached $150 earlier in its post-IPO run, but the shares have given back much of that advance amid a broader pullback in high-multiple diagnostics names and a modest earnings miss in August.
The path toward $125 would most likely require re-accelerating revenue growth, a clean third-quarter report, and renewed analyst target increases. BillionToOne reported trailing twelve-month revenue near $397 million, up roughly 90% year over year, yet its August quarter of about $109 million in revenue and EPS (earnings per share) of $0.15 both came in slightly below consensus estimates — a reminder that high expectations leave little room for error.
The most durable reference points are the 52-week range: a high near $150 and a low near $62. The stock has consolidated recently in the low-to-mid $100s, with $100 acting as a psychological level. The $110-to-$120 zone, where the stock traded through much of the late summer, could act as overhead resistance on the way toward $125, while the $90-to-$95 area sits below current price as a potential support level. The long-term trend structure remains constructive but unproven, given the shares are still well off their post-IPO peak.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state a specific timeframe. The next confirmed earnings report is scheduled for November 4, 2026, and will be pivotal for validating the growth trajectory after the August miss. Investors should also monitor analyst target revisions, any updates on reimbursement coverage for UNITY and Northstar, and broader sentiment toward high-valuation healthcare names, which can swing sharply with interest-rate expectations.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. Whether you are tracking a volatile growth name like BillionToOne or a diversified fund, automated signal tools can help surface actionable setups as they develop.
Can BillionToOne stock reach $125? The evidence is genuinely mixed. A central target of $125, derived from a $123 mean of seven verified analyst targets, sits about 21% above the current price — a substantial but achievable move given the stock has already traded near $150. The bull case rests on exceptional revenue growth, early profitability, and differentiated technology. The bear case rests on an extreme valuation, reimbursement uncertainty, and a recent earnings shortfall that showed how unforgiving the market can be. The wide $90-to-$145 analyst range underscores how much depends on execution. The November earnings report and subsequent analyst revisions will be the clearest near-term guideposts. No target, however calculated, is a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.